Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are well established as effective adjuncts to lifestyle modification in the treatment of type 2 diabetes (T2D) as monotherapy or in combination with oral glucose-lowering drugs insulin.
GLP-1 medications are most often used to treat type 2 diabetes and obesity. However, new research has found that they may have other applications. They may help lower the risk of opioid overdose as well as early death.
Semaglutide is the first GLP-1 RA in the EU approved for cardiovascular benefits in type 2 diabetes patients. The phase 3 SOUL trial showed a 14% reduction in cardiovascular events with semaglutide vs placebo.
SGLT2 inhibitors and GLP-1 receptor agonists (RAs), have transformed the management of type 2 diabetes (T2D), obesity, chronic kidney disease (CKD), and heart failure (HF). Their benefits extend well beyond glycemic control and weight loss and include cardiorenal (CR) protection.
The obesity-diabetes relationship and what it means for pharmacy benefits. Obesity is linked to several downstream health conditions caused by excess weight: cardiovascular disease, heart attacks, Type 2 diabetes and strokes.
Such details provide a deeper understanding and appreciation for Glp-1 Benefits In Type 2 Diabetes.
If you take a prescription weight loss drug such as Ozempic or Wegovy to help manage type 2 diabetes or support weight-related goals, heres news you need to know: Research shows that 92 percent of patients are overpaying for their GLP-1 medications.
